Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Autor:	Krupashankar, D.S., Dogra, Sunil, Kura, Mahendra, Saraswat, Abir, Budamakuntla, Leelavathy, Sumathy, T.K., Shah, Radha, Gopal, M.G., Narayana Rao, T., Srinivas, C.R., Bhat, Ramesh, Shetty, Narendra, Manmohan, G., Sai Krishna, Kotla, Padmaja, Dalavoi, Pratap, Dasiga Venkata Subrahmanya, Garg, Vijay, Gupta, Sandesh, Pandey, Neeraj, Khopkar, Uday, Montero, Enrique, Ramakrishnan, M.S., Nair, Pradip, Ganapathi, Prasanna C.
Zdroj:	In Journal of the American Academy of Dermatology September 2014 71(3):484-492
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect